JP2019511921A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511921A5 JP2019511921A5 JP2018545647A JP2018545647A JP2019511921A5 JP 2019511921 A5 JP2019511921 A5 JP 2019511921A5 JP 2018545647 A JP2018545647 A JP 2018545647A JP 2018545647 A JP2018545647 A JP 2018545647A JP 2019511921 A5 JP2019511921 A5 JP 2019511921A5
- Authority
- JP
- Japan
- Prior art keywords
- herpesvirus
- protein
- hvlp
- encoding
- ebv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022063477A JP7518123B2 (ja) | 2016-03-01 | 2022-04-06 | ヘルペスウイルス感染を処置するための手段及び方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16000493 | 2016-03-01 | ||
| EP16000493.3 | 2016-03-01 | ||
| LU93002 | 2016-03-17 | ||
| LU93002 | 2016-03-17 | ||
| PCT/EP2017/054615 WO2017148928A1 (en) | 2016-03-01 | 2017-02-28 | Means and methods for treating herpesvirus infection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022063477A Division JP7518123B2 (ja) | 2016-03-01 | 2022-04-06 | ヘルペスウイルス感染を処置するための手段及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511921A JP2019511921A (ja) | 2019-05-09 |
| JP2019511921A5 true JP2019511921A5 (enExample) | 2020-04-02 |
| JP7517792B2 JP7517792B2 (ja) | 2024-07-17 |
Family
ID=58191453
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545647A Active JP7517792B2 (ja) | 2016-03-01 | 2017-02-28 | ヘルペスウイルス感染を処置するための手段及び方法 |
| JP2022063477A Active JP7518123B2 (ja) | 2016-03-01 | 2022-04-06 | ヘルペスウイルス感染を処置するための手段及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022063477A Active JP7518123B2 (ja) | 2016-03-01 | 2022-04-06 | ヘルペスウイルス感染を処置するための手段及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11602560B2 (enExample) |
| EP (1) | EP3423092A1 (enExample) |
| JP (2) | JP7517792B2 (enExample) |
| CN (1) | CN109310753A (enExample) |
| CA (1) | CA3009115A1 (enExample) |
| WO (1) | WO2017148928A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11602560B2 (en) | 2016-03-01 | 2023-03-14 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Means and methods for treating herpesvirus infection |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| KR20220066413A (ko) | 2017-12-14 | 2022-05-24 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| EP3863668A1 (en) | 2018-10-12 | 2021-08-18 | Deutsches Krebsforschungszentrum | Epstein-barr virus-like particles with broadened antigenic spectrum |
| WO2020172522A1 (en) * | 2019-02-22 | 2020-08-27 | Ogembo Javier Gordon | Multivalent kaposi sarcoma-associated herpesvirus-like particles and uses thereof |
| US20230381300A1 (en) * | 2020-10-20 | 2023-11-30 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | METHOD FOR MANUFACTURING HEK293 CELL LINE, METHOD FOR MANUFACTURING EB-VLPs AND COMPOSITION COMPRISING SAID EB-VLPs |
| CN112451504B (zh) * | 2020-11-09 | 2022-10-18 | 四川大学华西医院 | 一种载EBV-LMP2 mRNA的核-壳纳米粒的制备方法及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140227305A1 (en) * | 2010-08-25 | 2014-08-14 | Romana Lange-Ruiss | Epstein-barr-virus vaccine |
| WO2013098364A1 (en) * | 2011-12-30 | 2013-07-04 | Deutsches Krebsforschungszentrum | Second generation virus-like particles (vlp) from epstein-barr viruses for vaccination purposes |
| US11602560B2 (en) | 2016-03-01 | 2023-03-14 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Means and methods for treating herpesvirus infection |
| EP3320917A1 (en) * | 2016-11-10 | 2018-05-16 | Deutsches Krebsforschungszentrum | Improved ebv vaccine |
-
2017
- 2017-02-28 US US16/080,292 patent/US11602560B2/en active Active
- 2017-02-28 WO PCT/EP2017/054615 patent/WO2017148928A1/en not_active Ceased
- 2017-02-28 JP JP2018545647A patent/JP7517792B2/ja active Active
- 2017-02-28 CN CN201780014496.XA patent/CN109310753A/zh active Pending
- 2017-02-28 EP EP17707855.7A patent/EP3423092A1/en active Pending
- 2017-02-28 CA CA3009115A patent/CA3009115A1/en active Pending
-
2022
- 2022-04-06 JP JP2022063477A patent/JP7518123B2/ja active Active
-
2023
- 2023-03-10 US US18/182,212 patent/US12414989B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511921A5 (enExample) | ||
| Van Zyl et al. | Progress in EBV vaccines | |
| Cheng et al. | Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22–antigen fusion | |
| Perez et al. | Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice | |
| Pavlova et al. | An Epstein-Barr virus mutant produces immunogenic defective particles devoid of viral DNA | |
| RU2733834C1 (ru) | Искусственный ген EctoS_SC2, кодирующий эктодомен гликопротеина S коронавируса SARS-CoV-2 с C-концевым тримеризующим доменом, рекомбинантная плазмида pStem-rVSV-EctoS_SC2, обеспечивающая экспрессию искусственного гена, и рекомбинантный штамм вируса везикулярного стоматита rVSV-EctoS_SC2, используемый для создания вакцины против коронавируса SARS-CoV-2 | |
| Sun et al. | The status and prospects of Epstein–Barr virus prophylactic vaccine development | |
| JP2017205126A5 (enExample) | ||
| RU2019139064A (ru) | Композиции и способы для лечения цитомегаловируса | |
| JP2021036882A5 (enExample) | ||
| HRP20211015T1 (hr) | Cjepivo protiv citomegalovirusa (cmv) | |
| Jean-Pierre et al. | Main targets of interest for the development of a prophylactic or therapeutic Epstein-Barr virus vaccine | |
| KR101839535B1 (ko) | 융합 단백질 함유 인간 세포거대바이러스에 의한 포유동물 세포의 감염 후 분비되는 바이러스 입자 및 이의 용도 | |
| Reap et al. | Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus | |
| Shen et al. | Optimization and scale-up of cell culture and purification processes for production of an adenovirus-vectored tuberculosis vaccine candidate | |
| RU2010111725A (ru) | Рекомбинантный герпесвирус кои (khv) или герпесвирус 3 семейства карповых (cyhv-3) и вакцина для профилактики заболевания, вызванного khv/cyhv-3 у cyprinus carpio или cyprinus carpio koi | |
| Wang et al. | Construction of a recombinant duck enteritis virus (DEV) expressing hemagglutinin of H5N1 avian influenza virus based on an infectious clone of DEV vaccine strain and evaluation of its efficacy in ducks and chickens | |
| JP2021500911A (ja) | アデノウイルス及びその用途 | |
| Bailer et al. | Herpesviral vectors and their application in oncolytic therapy, vaccination, and gene transfer | |
| Guo et al. | Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines | |
| Jindra et al. | Attenuated recombinant influenza A virus expressing HPV16 E6 and E7 as a novel therapeutic vaccine approach | |
| Di et al. | The self-assembled nanoparticle-based multi-epitope influenza mRNA vaccine elicits protective immunity against H1N1 and B influenza viruses in mice | |
| Kanai et al. | The vIL-10 gene of the Epstein-Barr virus (EBV) is conserved in a stable manner except for a few point mutations in various EBV isolates | |
| Lindquester et al. | Epstein-Barr virus IL-10 gene expression by a recombinant murine gammaherpesvirus in vivo enhances acute pathogenicity but does not affect latency or reactivation | |
| Wang et al. | Specific cellular immune responses in mice immunized with DNA, adeno-associated virus and adenoviral vaccines of Epstein-Barr virus-LMP2 alone or in combination |